Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More
Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
CADILA HEALTHCARE Mar-20 |
ACTAVIS Dec-18 |
CADILA HEALTHCARE/ ACTAVIS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 352 | 14,427 | - | |
Low | Rs | 207 | 9,678 | - | |
Sales per share (Unadj.) | Rs | 139.2 | 3,539.0 | - | |
Earnings per share (Unadj.) | Rs | 11.8 | -1,139.9 | - | |
Cash flow per share (Unadj.) | Rs | 18.6 | 372.9 | - | |
Dividends per share (Unadj.) | Rs | 3.50 | 0 | - | |
Dividend yield (eoy) | % | 1.3 | 0 | - | |
Book value per share (Unadj.) | Rs | 101.4 | 14,596.8 | - | |
Shares outstanding (eoy) | m | 1,023.74 | 332.60 | - | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 2.0 | 3.4 | 58.9% | |
Avg P/E ratio | x | 23.7 | -10.6 | -224.6% | |
P/CF ratio (eoy) | x | 15.0 | 32.3 | 46.6% | |
Price / Book Value ratio | x | 2.8 | 0.8 | 333.9% | |
Dividend payout | % | 29.8 | 0 | - | |
Avg Mkt Cap | Rs m | 286,033 | 4,008,703 | 7.1% | |
No. of employees | `000 | 13.4 | 16.9 | 79.3% | |
Total wages/salary | Rs m | 24,145 | 0 | - | |
Avg. sales/employee | Rs Th | 10,632.7 | 69,649.6 | 15.3% | |
Avg. wages/employee | Rs Th | 1,801.2 | 0 | - | |
Avg. net profit/employee | Rs Th | 898.5 | -22,434.2 | -4.0% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 142,531 | 1,177,079 | 12.1% | |
Other income | Rs m | 1,139 | 22,510 | 5.1% | |
Total revenues | Rs m | 143,670 | 1,199,588 | 12.0% | |
Gross profit | Rs m | 24,198 | 30,845 | 78.4% | |
Depreciation | Rs m | 6,965 | 503,176 | 1.4% | |
Interest | Rs m | 3,418 | 67,924 | 5.0% | |
Profit before tax | Rs m | 14,954 | -517,745 | -2.9% | |
Minority Interest | Rs m | 288 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 132,046 | 0.0% | |
Tax | Rs m | 3,198 | -6,561 | -48.7% | |
Profit after tax | Rs m | 12,044 | -379,138 | -3.2% | |
Gross profit margin | % | 17.0 | 2.6 | 647.9% | |
Effective tax rate | % | 21.4 | 1.3 | 1,687.5% | |
Net profit margin | % | 8.5 | -32.2 | -26.2% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 87,154 | 482,776 | 18.1% | |
Current liabilities | Rs m | 82,694 | 427,080 | 19.4% | |
Net working cap to sales | % | 3.1 | 4.7 | 66.1% | |
Current ratio | x | 1.1 | 1.1 | 93.2% | |
Inventory Days | Days | 71 | 20 | 364.7% | |
Debtors Days | Days | 94 | 66 | 141.5% | |
Net fixed assets | Rs m | 133,236 | 133,239 | 100.0% | |
Share capital | Rs m | 1,024 | 0 | - | |
Net worth | Rs m | 103,757 | 4,854,900 | 2.1% | |
Long term debt | Rs m | 32,146 | 1,709,586 | 1.9% | |
Total assets | Rs m | 236,866 | 7,589,313 | 3.1% | |
Interest coverage | x | 5.4 | -6.6 | -81.2% | |
Debt to equity ratio | x | 0.3 | 0.4 | 88.0% | |
Sales to assets ratio | x | 0.6 | 0.2 | 388.0% | |
Return on assets | % | 6.5 | -4.1 | -159.2% | |
Return on equity | % | 11.6 | -7.8 | -148.6% | |
Return on capital | % | 13.7 | -4.8 | -283.6% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 25,054 | 420,526 | 6.0% | |
From Investments | Rs m | -10,123 | 231,024 | -4.4% | |
From Financial Activity | Rs m | -10,942 | -721,748 | 1.5% | |
Net Cashflow | Rs m | 3,989 | -69,848 | -5.7% |
Compare CADILA HEALTHCARE With: MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Compare CADILA HEALTHCARE With: ALEMBIC UNICHEM LAB STRIDES PHARMA SCIENCE WYETH FRESENIUS KABI ONCO.
Indian share markets witnessed huge selling pressure today as fears that the government could go for stricter lockdowns.
For the quarter ended December 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 40.6% YoY). Sales on the other hand came in at Rs 38 bn (up 4.3% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.
For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
More Views on NewsIn this video, I'll tell you why I am recommending caution in the market at this time.
A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.
In this video I'll show you exactly how I go about picking stocks for trading.
100 baggers of the last decade share this common trait. Here's how to use it to nail future multibaggers.
More